Becton, Dickinson and Company $BDX Shares Acquired by Exchange Traded Concepts LLC

Key Points

• Exchange Traded Concepts LLC increased its stake in Becton, Dickinson and Company by 146.2% during the second quarter, owning 48,857 shares valued at approximately $8.4 million.
• Insider trading activity is notable, with executive Michael David Garrison selling 1,185 shares and director Claire Fraser selling 917 shares, representing significant decreases in their holdings.
• Becton, Dickinson and Company reported earnings per share (EPS) of $3.68 for the last quarter, exceeding analysts' expectations, while also announcing a quarterly dividend of $1.04 per share.

Exchange Traded Concepts LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 146.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 48,857 shares of the medical instruments supplier's stock after acquiring an additional 29,009 shares during the period. Exchange Traded Concepts LLC's holdings in Becton, Dickinson and Company were worth $8,416,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also made changes to their positions in the company. Saudi Central Bank bought a new position in Becton, Dickinson and Company in the 1st quarter worth $26,000. Smallwood Wealth Investment Management LLC bought a new position in shares of Becton, Dickinson and Company in the first quarter valued at about $27,000. REAP Financial Group LLC increased its position in Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares in the last quarter. Alpine Bank Wealth Management bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Finally, Cornerstone Planning Group LLC boosted its holdings in Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 99 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,965 shares of company stock valued at $551,536. 0.36% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on BDX. Barclays lowered their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Piper Sandler reissued a "neutral" rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Wells Fargo & Company lifted their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Finally, Argus lifted their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $213.30.

Becton, Dickinson and Company Price Performance

NYSE:BDX traded down $1.10 during trading hours on Friday, reaching $187.27. The company had a trading volume of 2,750,943 shares, compared to its average volume of 1,535,837. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The firm has a market capitalization of $53.68 billion, a PE ratio of 33.68, a PEG ratio of 1.51 and a beta of 0.27. The stock has a 50-day moving average of $187.65 and a two-hundred day moving average of $190.16.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's payout ratio is presently 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.